title: Response to "Letter to the Editor Concerning the Paper by Fung et al titled 'Differential Effects of Cyproterone Acetate vs Spironolactone on Serum High-Density Lipoprotein and Prolactin Concentrations in the Hormonal Treatment of Transgender Women".
authors.affiliation: Division of Endocrinology, Department of Medicine, Michael Garron Hospital, Toronto, ON, Canada. Electronic address: rfung@tegh.on.ca.
authors.forename: Raymond
authors.initials: R
authors.lastname: Fung
authors.affiliation: Division of Endocrinology, Department of Medicine, Women's College Hospital, Toronto, ON, Canada.
authors.forename: Iliana
authors.initials: I
authors.lastname: Lega
mesh_terms: D000726:Androgen Antagonists; D003534:Cyproterone; D017373:Cyproterone Acetate; D004997:Ethinyl Estradiol; D005260:Female; D006801:Humans; D008075:Lipoproteins, HDL; D011388:Prolactin / Q000097:blood*; D013148:Spironolactone; D063106:Transgender Persons; D008297:Male
chemical_list: D000726:Androgen Antagonists; D008075:Lipoproteins, HDL; D013148:Spironolactone; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; D011388:Prolactin; D003534:Cyproterone